A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)

被引：0
|
作者：
A Bensalem
K Bouzid
机构：
[1] Chu Dr Benbardis,Medical Oncology
来源：
Breast Cancer Research | / 7卷
关键词：
Breast Cancer; Doxorubicin; Neutropenia; Gemcitabine; Partial Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer MBC
    Bensalem, A
    Bouzid, K
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 1) : S21 - S21
  • [2] A phase II trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC).
    Bensalem, A
    Bouzid, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 72S - 72S
  • [3] Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC).
    Khoo, KS
    Zaidi, M
    Srimuninnimit, V
    Jiang, ZF
    Prem Kumar, P
    Bustam, A
    Villalon, AH
    Lehnert, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 54S - 54S
  • [4] Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients
    Jacquin, Jean-Philippe
    Chargari, Cyrus
    Thorin, Julie
    Mille, Dominique
    Melis, Adrien
    Orfeuvre, Hubert
    Clavreul, Guillaume
    Chaigneau, Loic
    Nourissat, Alice
    Dumanoir, Chantal
    Savary, Jacqueline
    Merrouche, Yacine
    Magne, Nicolas
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (01): : 18 - 21
  • [5] Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: A phase II study.
    Fabi, A
    Papaldo, P
    Ciccarese, M
    Salesi, N
    Lorusso, V
    Ferretti, G
    Carlini, P
    Sacchi, I
    Cecere, F
    Cognetti, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 80S - 80S
  • [6] Gemcitabine (G) and Doxorubicin (DXR) as first-line treatment of metastatic breast cancer (MBC): Preliminary results.
    Bensalem, A
    Bouzid, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [7] A phase II study of pemetrexed and doxorubicin in patients with advanced or metastatic breast cancer (MBC)
    Blasinska-Morawiec, M.
    Martin, M.
    Salas, F.
    Falcon, S.
    Rolski, J.
    Ferrari, B. L.
    Guedez, N.
    Simms, L.
    Gulyas, S.
    Melemed, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Phase II study biweekly paclitaxel, doxorubicin and gemcitabine as first line chemotherapy for metastatic breast cancer (MBC).
    Sanchez-Rovira, P
    González, E
    Porras, I
    Jaén, A
    Medina, B
    Fernández, M
    Mohedano, N
    Lozano, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S52 - S52
  • [9] Final results of gemcitabine (G) and epirubicin (E) phase II trial in metastatic breast cancer (MBC) patients (pts).
    Fumoleau, P
    Viens, P
    Dieras, V
    Pujade-Lauraine, E
    Serin, D
    Petit, T
    Espie, M
    Kayitalire, L
    Robert, C
    Pouillart, P
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S90 - S90
  • [10] Phase II trial of biweekly gemcitabine, paclitaxel, and bevacizumab as frontline therapy for metastatic breast cancer (MBC)
    Nahleh, Z. A.
    Gupta, R.
    Abrams, J.
    Gartner, E. M.
    Reichle, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345